nodes	percent_of_prediction	percent_of_DWPC	metapath
Labetalol—Erythema facial—Hydrochlorothiazide—nephrolithiasis	0.0876	0.108	CcSEcCtD
Labetalol—Local swelling—Hydrochlorothiazide—nephrolithiasis	0.0458	0.0565	CcSEcCtD
Labetalol—Raised liver function tests—Hydrochlorothiazide—nephrolithiasis	0.0347	0.0428	CcSEcCtD
Labetalol—Epigastric pain—Hydrochlorothiazide—nephrolithiasis	0.0331	0.0409	CcSEcCtD
Labetalol—Joint swelling—Hydrochlorothiazide—nephrolithiasis	0.0326	0.0403	CcSEcCtD
Labetalol—Sleep disturbance—Hydrochlorothiazide—nephrolithiasis	0.0285	0.0352	CcSEcCtD
Labetalol—Respiratory distress—Hydrochlorothiazide—nephrolithiasis	0.0252	0.0311	CcSEcCtD
Labetalol—Ventricular arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.0216	0.0267	CcSEcCtD
Labetalol—ADRB1—Endothelin Pathways—ADCY10—nephrolithiasis	0.021	0.116	CbGpPWpGaD
Labetalol—Numbness—Hydrochlorothiazide—nephrolithiasis	0.0193	0.0238	CcSEcCtD
Labetalol—Sensory loss—Hydrochlorothiazide—nephrolithiasis	0.0185	0.0228	CcSEcCtD
Labetalol—Jaundice cholestatic—Hydrochlorothiazide—nephrolithiasis	0.0182	0.0225	CcSEcCtD
Labetalol—Wheezing—Hydrochlorothiazide—nephrolithiasis	0.0155	0.0192	CcSEcCtD
Labetalol—Blood urea increased—Hydrochlorothiazide—nephrolithiasis	0.0151	0.0187	CcSEcCtD
Labetalol—ADRB3—Monoamine GPCRs—CHRM3—nephrolithiasis	0.0147	0.0814	CbGpPWpGaD
Labetalol—Sleep disorder—Hydrochlorothiazide—nephrolithiasis	0.0134	0.0166	CcSEcCtD
Labetalol—Nasal congestion—Hydrochlorothiazide—nephrolithiasis	0.0128	0.0157	CcSEcCtD
Labetalol—ADRB3—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.0124	0.0685	CbGpPWpGaD
Labetalol—Affect lability—Hydrochlorothiazide—nephrolithiasis	0.0114	0.0141	CcSEcCtD
Labetalol—Mood swings—Hydrochlorothiazide—nephrolithiasis	0.011	0.0136	CcSEcCtD
Labetalol—Liver function test abnormal—Hydrochlorothiazide—nephrolithiasis	0.0107	0.0132	CcSEcCtD
Labetalol—Orthostatic hypotension—Hydrochlorothiazide—nephrolithiasis	0.0106	0.0131	CcSEcCtD
Labetalol—Abdominal pain upper—Hydrochlorothiazide—nephrolithiasis	0.0106	0.0131	CcSEcCtD
Labetalol—Cramp muscle—Hydrochlorothiazide—nephrolithiasis	0.0105	0.0129	CcSEcCtD
Labetalol—Angina pectoris—Hydrochlorothiazide—nephrolithiasis	0.00978	0.0121	CcSEcCtD
Labetalol—Dysuria—Hydrochlorothiazide—nephrolithiasis	0.00939	0.0116	CcSEcCtD
Labetalol—Erectile dysfunction—Hydrochlorothiazide—nephrolithiasis	0.00925	0.0114	CcSEcCtD
Labetalol—Tolterodine—CHRM3—nephrolithiasis	0.00923	1	CrCbGaD
Labetalol—ADRB3—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.00902	0.0499	CbGpPWpGaD
Labetalol—ADRB1—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00873	0.0483	CbGpPWpGaD
Labetalol—Jaundice—Hydrochlorothiazide—nephrolithiasis	0.00873	0.0108	CcSEcCtD
Labetalol—Sweating—Hydrochlorothiazide—nephrolithiasis	0.00858	0.0106	CcSEcCtD
Labetalol—ADRB2—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00854	0.0473	CbGpPWpGaD
Labetalol—Epistaxis—Hydrochlorothiazide—nephrolithiasis	0.00844	0.0104	CcSEcCtD
Labetalol—Agranulocytosis—Hydrochlorothiazide—nephrolithiasis	0.00835	0.0103	CcSEcCtD
Labetalol—Bradycardia—Hydrochlorothiazide—nephrolithiasis	0.00818	0.0101	CcSEcCtD
Labetalol—Hepatitis—Hydrochlorothiazide—nephrolithiasis	0.00804	0.00992	CcSEcCtD
Labetalol—Hypoaesthesia—Hydrochlorothiazide—nephrolithiasis	0.008	0.00987	CcSEcCtD
Labetalol—Oedema peripheral—Hydrochlorothiazide—nephrolithiasis	0.00792	0.00977	CcSEcCtD
Labetalol—Visual impairment—Hydrochlorothiazide—nephrolithiasis	0.00774	0.00956	CcSEcCtD
Labetalol—Flushing—Hydrochlorothiazide—nephrolithiasis	0.00746	0.00921	CcSEcCtD
Labetalol—ADRB1—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00734	0.0406	CbGpPWpGaD
Labetalol—ADRB2—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00718	0.0397	CbGpPWpGaD
Labetalol—Alopecia—Hydrochlorothiazide—nephrolithiasis	0.0071	0.00877	CcSEcCtD
Labetalol—Erythema—Hydrochlorothiazide—nephrolithiasis	0.007	0.00864	CcSEcCtD
Labetalol—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.00673	0.0083	CcSEcCtD
Labetalol—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.00659	0.00814	CcSEcCtD
Labetalol—Tremor—Hydrochlorothiazide—nephrolithiasis	0.00655	0.00809	CcSEcCtD
Labetalol—Ill-defined disorder—Hydrochlorothiazide—nephrolithiasis	0.00649	0.00801	CcSEcCtD
Labetalol—Angioedema—Hydrochlorothiazide—nephrolithiasis	0.00639	0.00789	CcSEcCtD
Labetalol—Malaise—Hydrochlorothiazide—nephrolithiasis	0.00631	0.00779	CcSEcCtD
Labetalol—Vertigo—Hydrochlorothiazide—nephrolithiasis	0.00629	0.00776	CcSEcCtD
Labetalol—Syncope—Hydrochlorothiazide—nephrolithiasis	0.00627	0.00774	CcSEcCtD
Labetalol—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.00618	0.00763	CcSEcCtD
Labetalol—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.00615	0.00759	CcSEcCtD
Labetalol—Discomfort—Hydrochlorothiazide—nephrolithiasis	0.00588	0.00726	CcSEcCtD
Labetalol—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.00576	0.00711	CcSEcCtD
Labetalol—Oedema—Hydrochlorothiazide—nephrolithiasis	0.00571	0.00705	CcSEcCtD
Labetalol—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.00571	0.00705	CcSEcCtD
Labetalol—Shock—Hydrochlorothiazide—nephrolithiasis	0.00562	0.00693	CcSEcCtD
Labetalol—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.00552	0.00681	CcSEcCtD
Labetalol—ADRB1—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.00535	0.0296	CbGpPWpGaD
Labetalol—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.00534	0.00659	CcSEcCtD
Labetalol—ADRB2—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.00524	0.029	CbGpPWpGaD
Labetalol—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.00513	0.00633	CcSEcCtD
Labetalol—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.00509	0.00628	CcSEcCtD
Labetalol—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.00508	0.00627	CcSEcCtD
Labetalol—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00503	0.0062	CcSEcCtD
Labetalol—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.00492	0.00608	CcSEcCtD
Labetalol—Constipation—Hydrochlorothiazide—nephrolithiasis	0.00488	0.00603	CcSEcCtD
Labetalol—Pain—Hydrochlorothiazide—nephrolithiasis	0.00488	0.00603	CcSEcCtD
Labetalol—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.00471	0.00581	CcSEcCtD
Labetalol—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.00467	0.00576	CcSEcCtD
Labetalol—ADRB3—G alpha (s) signalling events—PTH—nephrolithiasis	0.00467	0.0258	CbGpPWpGaD
Labetalol—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.00454	0.0056	CcSEcCtD
Labetalol—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.00451	0.00557	CcSEcCtD
Labetalol—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.00451	0.00557	CcSEcCtD
Labetalol—ADRB3—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.00441	0.0244	CbGpPWpGaD
Labetalol—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.00421	0.00519	CcSEcCtD
Labetalol—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.0041	0.00506	CcSEcCtD
Labetalol—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.00404	0.00499	CcSEcCtD
Labetalol—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.00391	0.00482	CcSEcCtD
Labetalol—ADRB2—GPCRs, Other—CHRM3—nephrolithiasis	0.0038	0.021	CbGpPWpGaD
Labetalol—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00378	0.00466	CcSEcCtD
Labetalol—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00363	0.00448	CcSEcCtD
Labetalol—Rash—Hydrochlorothiazide—nephrolithiasis	0.0036	0.00444	CcSEcCtD
Labetalol—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.0036	0.00444	CcSEcCtD
Labetalol—Headache—Hydrochlorothiazide—nephrolithiasis	0.00358	0.00442	CcSEcCtD
Labetalol—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00339	0.00419	CcSEcCtD
Labetalol—ADRB3—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00284	0.0157	CbGpPWpGaD
Labetalol—ADRB1—G alpha (s) signalling events—PTH—nephrolithiasis	0.00277	0.0153	CbGpPWpGaD
Labetalol—ADRB2—G alpha (s) signalling events—PTH—nephrolithiasis	0.00271	0.015	CbGpPWpGaD
Labetalol—ADRB1—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.00262	0.0145	CbGpPWpGaD
Labetalol—ADRB2—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.00256	0.0142	CbGpPWpGaD
Labetalol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00243	0.0135	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—RGS14—nephrolithiasis	0.00214	0.0119	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—RGS14—nephrolithiasis	0.00195	0.0108	CbGpPWpGaD
Labetalol—ADRB3—GPCR ligand binding—CHRM3—nephrolithiasis	0.00185	0.0103	CbGpPWpGaD
Labetalol—CYP2D6—Biological oxidations—SLC26A1—nephrolithiasis	0.00177	0.00981	CbGpPWpGaD
Labetalol—ADRB3—GPCR ligand binding—PTH—nephrolithiasis	0.00169	0.00938	CbGpPWpGaD
Labetalol—ADRB1—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00169	0.00933	CbGpPWpGaD
Labetalol—ADRB2—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00165	0.00912	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—DGKH—nephrolithiasis	0.00145	0.00801	CbGpPWpGaD
Labetalol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00144	0.00799	CbGpPWpGaD
Labetalol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00141	0.00782	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—ADCY10—nephrolithiasis	0.00135	0.00749	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—DGKH—nephrolithiasis	0.00132	0.00728	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—RGS14—nephrolithiasis	0.00127	0.00704	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—RGS14—nephrolithiasis	0.00124	0.00689	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—RGS14—nephrolithiasis	0.00116	0.0064	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—RGS14—nephrolithiasis	0.00115	0.00636	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—RGS14—nephrolithiasis	0.00113	0.00626	CbGpPWpGaD
Labetalol—ADRB1—GPCR ligand binding—CHRM3—nephrolithiasis	0.0011	0.00609	CbGpPWpGaD
Labetalol—ADRB2—GPCR ligand binding—CHRM3—nephrolithiasis	0.00108	0.00595	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—CHRM3—nephrolithiasis	0.00105	0.00579	CbGpPWpGaD
Labetalol—ADRB1—GPCR ligand binding—PTH—nephrolithiasis	0.00101	0.00557	CbGpPWpGaD
Labetalol—ADRB2—GPCR ligand binding—PTH—nephrolithiasis	0.000984	0.00544	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—PTH—nephrolithiasis	0.000958	0.0053	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—CHRM3—nephrolithiasis	0.000951	0.00526	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—PTH—nephrolithiasis	0.00087	0.00481	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—DGKH—nephrolithiasis	0.00086	0.00476	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—DGKH—nephrolithiasis	0.000841	0.00465	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—ADCY10—nephrolithiasis	0.000803	0.00444	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—ADCY10—nephrolithiasis	0.000785	0.00435	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—DGKH—nephrolithiasis	0.000781	0.00432	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—DGKH—nephrolithiasis	0.000777	0.0043	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000777	0.0043	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—DGKH—nephrolithiasis	0.000764	0.00423	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—RGS14—nephrolithiasis	0.000683	0.00378	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—RGS14—nephrolithiasis	0.000668	0.0037	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000621	0.00344	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000608	0.00336	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—PTH—nephrolithiasis	0.000568	0.00315	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—CHRM3—nephrolithiasis	0.000564	0.00312	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—CHRM3—nephrolithiasis	0.000562	0.00311	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—PTH—nephrolithiasis	0.000556	0.00308	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—CHRM3—nephrolithiasis	0.000552	0.00306	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—PTH—nephrolithiasis	0.000516	0.00286	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—PTH—nephrolithiasis	0.000514	0.00284	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—PTH—nephrolithiasis	0.000505	0.00279	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—DGKH—nephrolithiasis	0.000461	0.00255	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000461	0.00255	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—DGKH—nephrolithiasis	0.000451	0.0025	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000451	0.0025	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—GRHPR—nephrolithiasis	0.0004	0.00221	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—AGXT—nephrolithiasis	0.000356	0.00197	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CHRM3—nephrolithiasis	0.000333	0.00184	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CHRM3—nephrolithiasis	0.000326	0.0018	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PTH—nephrolithiasis	0.000305	0.00169	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—SLC26A1—nephrolithiasis	0.000303	0.00168	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—APRT—nephrolithiasis	0.000303	0.00168	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PTH—nephrolithiasis	0.000298	0.00165	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—SPP1—nephrolithiasis	0.000258	0.00143	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—AQP1—nephrolithiasis	0.000216	0.0012	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CHRM3—nephrolithiasis	0.000195	0.00108	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—SPP1—nephrolithiasis	0.000153	0.000847	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—SPP1—nephrolithiasis	0.00015	0.000829	CbGpPWpGaD
